Flag of the European Union EU Clinical Trials Register Help

Clinical trials for GINA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    348 result(s) found for: GINA. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-003892-35 Sponsor Protocol Number: AL 0104 av Start Date*: 2005-04-01
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of...
    Medical condition: IgE-mediated allergic disease in adults and children manifested as bronchial asthma (GINA II and III) +/-allergic rhinitis/rhinoconjunctivitis, triggered by non-eliminable house dust mite allergens.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002391-97 Sponsor Protocol Number: PML_DOC_0802 Start Date*: 2008-06-19
    Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine
    Full Title: Open-label, prospective study to assess the effects of formoterol and beclometasone dipropionate combination therapy on central and peripheral airway dimensions in asthmatic patients
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001099-11 Sponsor Protocol Number: CIGE025A2425 Start Date*: 2005-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in ...
    Medical condition: Severe persistent allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NO (Completed) IE (Completed) ES (Completed) DK (Completed) SE (Completed) DE (Completed) HU (Completed) PT (Not Authorised) IT (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000302-28 Sponsor Protocol Number: EffICIENCY Start Date*: 2020-05-04
    Sponsor Name:Mundipharma Pharmaceuticals S.L.
    Full Title: Open randomized low interventional clinical trial to compare efficiency in symptom control between fluticasone propionate/formoterol k-haler at medium strength versus an high strength ICS/LABA for ...
    Medical condition: Persistent moderate asthma uncontrolled
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003991-39 Sponsor Protocol Number: I-025 Start Date*: 2005-12-08
    Sponsor Name:insaf, Institut für Atemwegsforschung GmbH
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR™) 10 MG ONCE DAILY OR ...
    Medical condition: Intermittend or mild asthma according to the definition of the Global Initiative ofor Asthma (GINA) guidelines step 1 or step 2 (2004)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003763-22 Sponsor Protocol Number: 1.027.19 Start Date*: 2020-01-23
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: A Pragmatic Proof of Concept Study to Evaluate the Effect of Benralizumab on Mannitol Challenge in Severe Eosinophilic Asthma
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-000025-35 Sponsor Protocol Number: Al0204AV Start Date*: 2005-04-05
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of...
    Medical condition: IgE-mediated allergic diseases including allergic rhinitis/rhinoconjunctivitis, allergic bronchial asthma (GINA I and II) triggered by birch pollen allergens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001027-59 Sponsor Protocol Number: NEO-040 Start Date*: 2008-10-21
    Sponsor Name:University of Dundee
    Full Title: A Randomised, Double-Blind, Double-Dummy Cross-Over Study to demonstrate Superiority of Fluticasone/ Salmeterol pMDI over double the dose of Fluticasone pMDI on Methacholine Hyper-Reactivity in Pat...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000513-29 Sponsor Protocol Number: CLU-2008-001 Start Date*: 2008-09-30
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact...
    Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002391-39 Sponsor Protocol Number: CLI-05993AB1-06 Start Date*: 2021-11-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 μg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF B...
    Medical condition: ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2- AGONISTS
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) SK (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed) LV (Completed) ES (Ongoing) FI (Completed) GR (Completed) NL (Completed) BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004966-13 Sponsor Protocol Number: CQAW039A2208 Start Date*: 2011-12-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 on sputum eosinophil levels and other efficacy outcomes in patients with sputum eosinophilia and pers...
    Medical condition: sputum eosinophilia and moderate-to-severe asthma (GINA 2-5) incompletely controlled on current therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10062305 Sputum eosinophils increased LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003249-16 Sponsor Protocol Number: PML_DOC_1102 Start Date*: 2012-01-06
    Sponsor Name:University Hospital of Antwerp
    Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003070-39 Sponsor Protocol Number: CYT003-QbG1012 Start Date*: 2012-11-26
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard T...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003612-28 Sponsor Protocol Number: 206785 Start Date*: 2021-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomised, double-blind, double-dummy, parallel group,multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and ad...
    Medical condition: Severe asthma with an eosinophilic phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) SI (Trial now transitioned) NO (Trial now transitioned) PL (Completed) FI (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001560-11 Sponsor Protocol Number: CQAW039A2315 Start Date*: 2017-03-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with un...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) LV (Prematurely Ended) EE (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) LT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended) BG (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000172-98 Sponsor Protocol Number: Start Date*: 2015-03-24
    Sponsor Name:The University of Leicester
    Full Title: An Open Label Oxygen Enhanced Imaging Biomarker Study to Assess the Role of Fluticasone/Formoterol upon Airway Function in Moderate to Severe Persistent Asthma.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000934-11 Sponsor Protocol Number: Al0106ac Start Date*: 2006-08-11
    Sponsor Name:Alllergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparatio...
    Medical condition: IgE-mediated allergic disease in adults manifested as rhinitis/ rhinoconjunctivitis and/or allergic asthma bronchiale (GINA I and II) triggered by non eliminable house dust mite allergens.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004756-69 Sponsor Protocol Number: M/100977/24 Start Date*: 2008-10-21
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A randomised, double-blind, placebo-controlled, 4-way crossover clinical trial to assess the efficacy, safety, tolerability and pharmacokinetics of single doses of LAS100977 administered by inhalat...
    Medical condition: Adult male subjects, aged 18 to 70 years, clinically diagnosed of persistent asthma (according to GINA guidelines 2007 update) for at least 6 months before screening, but who are otherwise in good ...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010914-31 Sponsor Protocol Number: CHD-PI08 Start Date*: 2009-12-02
    Sponsor Name:Dr. Christian Domingo
    Full Title: Eficacia clínica y cambios histológicos secundarios al tratamiento con omalizumab en asmáticos alérgicos en estadio V de la gina
    Medical condition: Asma
    Disease: Version SOC Term Classification Code Term Level
    9 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007244-33 Sponsor Protocol Number: LPA112046 Start Date*: 2009-04-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:26:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA